Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biosynex SA ( (FR:ALBIO) ) has shared an update.
Biosynex SA reported a 9% increase in revenue for 2024, reaching €101.4 million, driven by export sales and the Pharmacy Division’s resilience. The company is undergoing restructuring efforts, including renegotiating bank debt, closing unprofitable sites, and reducing staff, aiming to enhance operational profitability and align expenses with activity levels. These efforts are expected to save over €7 million annually from 2025, positioning Biosynex for improved financial stability and market competitiveness.
More about Biosynex SA
Biosynex SA operates in the healthcare industry, focusing on pharmacy and diagnostic products. The company is expanding internationally and has a strong presence in both Europe and the USA, with a significant emphasis on export growth.
YTD Price Performance: 55.52%
Average Trading Volume: 384
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €22.71M
See more data about ALBIO stock on TipRanks’ Stock Analysis page.